The US Food and Drug Administration (FDA) in December rejected the new antibiotic solithromycin over liver toxicity fears, putting the future of the drug in doubt and sending a chill through companies working on novel antimicrobials. “The problems with solithromycin are going to hit the whole sector hard,” says Lloyd Czaplewski, director of Chemical Biology […]